Event-Driven Stocks

Kezar Life Sciences, Inc.

KZRNasdaq

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 2 good● 1 warning● 1 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$0$0$7.0M$0$0—
Operating income−$59.1M−$90.6M−$111.4M−$71.2M−$54.7M−$43.0M
Net income−$56.0M−$83.7M−$101.9M−$68.2M−$54.6M−$10.0M
Total assets$76.6M$144.7M$221.2M$299.6M$217.9M$151.8M
Total liabilities$6.6M$27.8M$33.7M$29.7M$21.1M$10.9M
Equity$70.1M$116.9M$187.6M$269.9M$196.9M$141.0M
EPS (diluted)$-7.66$-11.49$-14.04$-10.13$-1.04$-0.95
Shares out.7.3M72.8M70.8M56.7M48.1M38.2M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
—
Net margin
—
Return on equity
−80.0%
Return on assets
−73.1%
Return on capital (ROCE)
−84.4%
Liabilities / assets
8.6%
Debt / equity
0.09×
Book value / share
$9.59
Revenue growth (YoY)
—
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
-8.93distress
Accruals / assets
−5.6%clean
Piotroski F-Score
4/8mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
52
/ 100
Profitability 0Growth n/aCatalyst 67Earnings quality 67Financial strength 75

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 1 severe● 1 warning● 2 good
  • Altman Z″ in the distress zone
  • Negative operating cash flow
  • Conservative leverage (liabilities < 50% of assets)
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
Apr 30, 2026158,5192.3+4.6%
Apr 15, 2026151,6021.4-24.7%
Mar 31, 2026201,3301.9+4.7%
Mar 13, 2026192,3065.2+9.2%
Feb 27, 2026176,0564.3-4.3%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (2)